Federal regulators have identified a common thread running through a string of injuries at wellness clinics: at least 30 patients had adverse reactions after intravenous glutathione, and the pharmacies involved all bought the same ingredient from the same supplier lot.
The Food and Drug Administration named the source in an alert issued August 27. Different compounding pharmacies all obtained their glutathione from Medisca Inc., whose U.S. headquarters is in Plattsburgh, New York, under lot number 229536. That material was labeled as dietary supplement grade, which the agency states is not an appropriate ingredient for making injectable drugs.
